非小细胞肺癌脑转移患者放疗后实施贝伐珠单抗联合卡铂与紫杉醇治疗的临床效果  

Clinical Efficacy of Bevacizumab Combined with Carboplatin and Paclitaxel in the Treatment of Non-small Cell Lung Cancer Patients with Brain Metastases

作　　者：肖书超 吴娅丽 蔡利红 XIAO Shuchao;WU YAli;CAI Lihong(Kaifeng Cancer Hospital,Kaifeng,475000)

机构地区：[1]河南省开封市肿瘤医院,475000

出　　处：《实用癌症杂志》2025年第3期475-478,共4页The Practical Journal of Cancer

摘　　要：目的 探究贝伐珠单抗联合卡铂与紫杉醇用于非小细胞肺癌(NSCLC)脑转移患者放疗后的治疗效果。方法 收集58例NSCLC脑转移放疗患者临床资料纳入研究。依照患者病情制定适宜的干预方案,根据患者治疗方案的不同进行分组,其中实施卡铂与紫杉醇治疗的29例患者作为对照组,实施贝伐珠单抗联合卡铂与紫杉醇治疗的29例患者作为观察组。比较2组治疗效果、安全性及KPS评分。结果 观察组客观缓解率(82.76%)、疾病控制率(93.10%)均高于对照组[(58.62%)、(72.41%)],差异有统计学意义(χ^(2)=4.078,P=0.044;χ^(2)=4.350,P=0.037)。2组不良反应发生率比较,差异无统计学意义(χ^(2)=0.145,P=0.703)。干预前,2组KPS评分差异不显著(t=0.132,P=0.896);干预后,2组评分均较干预前显著提升(t=11.570,P=0.000;t=10.338,P=0.000),且观察组KPS评分高于对照组,差异有统计学意义(t=2.352,P=0.022)。结论 贝伐珠单抗联合卡铂与紫杉醇能够提升NSCLC脑转移放疗患者的治疗效果,控制疾病,提高患者的生存质量,且安全性较高。Objective To explore the therapeutic effect of bevacizumab combined with carboplatin and paclitaxel on non-small cell lung cancer(NSCLC)patients with brain metastases.Methods The clinical data of 58 patients with NSCLC were collected and studied.The appropriate intervention plan was developed according to the patients'condition,and the patients were grouped according to the different treatment plans.29 patients receiving carboplatin and paclitaxel were taken as the control group,and 29 patients receiving bevacizumab combined carboplatin and paclitaxel were taken as the observation group.The therapeutic effect,safety and KPS score of the two groups were compared.Results The objective remission rate(82.76%)and disease control rate(93.10%)in observation group were higher than those in control group(58.62%)and control group(72.41%),and the differences were statistically significant(χ^(2)=4.078,P=0.044,2=4.350,P=0.037).There was no significant difference in the incidence of adverse reactions between the 2 groups(χ^(2)=0.145,P=0.703).Before intervention,there was no significant difference in KPS score between the two groups(t=0.132,P=0.896).After intervention,the scores of the 2 groups were significantly improved compared with those before intervention(t=11.570,P=0.000,t=10.338,P=0.000),and the KPS score of the observation group was higher than that of the control group,the difference was statistically significant(t=2.352,P=0.022).Conclusion Bevacizumab combined with carboplatin and paclitaxel can improve the therapeutic effect of patients with NSCLC brain metastasis radiotherapy,control the disease,and significantly improve the quality of life of patients with high safety.

关 键 词：贝伐珠单抗 卡铂 紫杉醇 非小细胞肺癌 脑转移 放疗 疾病控制 

分 类 号：R734.2[医药卫生—肿瘤]